…
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Sorrento Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, cell therapies and non-opioid pain treatments; its long-term growth may be driven by clinical trial readouts, regulatory approvals and licensing or partnership opportunities. Investors may find it attractive for a diversified pipeline and platform capabilities that could support commercialization if development programs succeed.
Major risks are high clinical and regulatory failure probability, ongoing need for external financing with dilution risk, and operational or governance uncertainty from prior restructurings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -561.75M | -462.53M | -310.58M | -359.58M | -213.78M |
| Minority interest | -4.91M | -0.81M | -15.95M | -70.94M | -8.99M |
| Net income | -559.33M | -429.01M | -308.57M | -359.10M | -203.54M |
| Selling general administrative | 182.34M | 196.86M | 116.18M | 103.56M | 63.64M |
| Gross profit | 29.39M | 39.87M | 30.05M | 19.20M | 14.13M |
| Reconciled depreciation | 13.24M | 12.46M | 11.01M | 10.99M | 9.05M |
| Ebit | -382.00M | -399.77M | -206.58M | -198.14M | -152.18M |
| Ebitda | -364.52M | -383.45M | -191.87M | -183.10M | -143.13M |
| Depreciation and amortization | 17.48M | 16.32M | 14.71M | 15.04M | 9.05M |
| Non operating income net other | -67.28M | -22.98M | -51.73M | -67.75M | -10.60M |
| Operating income | -378.50M | -368.05M | -201.53M | -195.18M | -150.43M |
| Other operating expenses | 441.34M | 420.95M | 241.51M | 226.61M | 150.67M |
| Interest expense | 8.57M | 10.22M | 20.18M | 36.14M | 57.63M |
| Tax provision | -2.42M | -33.52M | -2.01M | -0.47M | -6.27M |
| Interest income | - | - | 0.02M | 1.09M | 0.92M |
| Net interest income | -8.57M | -10.22M | -20.16M | -35.05M | -56.71M |
| Non recurring | 188.94M | - | - | - | - |
| Income tax expense | -2.42M | -33.52M | -2.01M | -0.47M | -6.27M |
| Total revenue | 62.84M | 52.90M | 39.99M | 31.43M | 21.19M |
| Total operating expenses | 407.89M | 407.92M | 231.57M | 214.38M | 143.61M |
| Cost of revenue | 33.45M | 13.03M | 9.94M | 12.24M | 7.06M |
| Total other income expense net | -183.25M | -94.48M | -109.05M | -164.39M | -63.36M |
| Net income from continuing ops | -559.33M | -429.01M | -308.57M | -359.10M | -207.51M |
| Net income applicable to common shares | -572.84M | -428.32M | -298.46M | -292.07M | -203.54M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 472.84M | 694.82M | 535.82M | 557.63M | 624.09M |
| Intangible assets | 136.90M | 259.70M | 73.67M | 63.31M | 66.28M |
| Other current assets | 3.14M | 7.48M | 3.72M | 27.19M | 16.17M |
| Total liab | 494.51M | 616.69M | 395.09M | 524.88M | 416.59M |
| Total stockholder equity | -21.67M | 78.13M | 140.73M | 32.76M | 207.50M |
| Deferred long term liab | 0.89M | 38.13M | 42.32M | 44.04M | 15.56M |
| Other current liab | 249.59M | 67.41M | 40.45M | 44.35M | 34.95M |
| Common stock | 0.05M | 0.03M | 0.03M | 0.02M | 0.01M |
| Capital stock | 0.05M | 0.03M | 0.03M | 0.02M | 0.01M |
| Retained earnings | -1959.45M | -1386.60M | -958.28M | -659.82M | -367.75M |
| Other liab | - | 283.18M | 156.05M | 158.47M | 131.83M |
| Good will | 80.27M | 79.53M | 43.55M | 38.30M | 38.30M |
| Other assets | - | 1216.65M | 300.50M | 49.92M | 50.57M |
| Cash | 23.63M | 36.66M | 56.46M | 22.52M | 158.74M |
| Total current liabilities | 327.92M | 139.45M | 96.48M | 115.21M | 61.62M |
| Current deferred revenue | 0.65M | 1.11M | 4.49M | 3.64M | 2.70M |
| Net debt | 110.87M | 200.91M | 112.93M | 268.26M | 74.55M |
| Short term debt | 30.17M | 43.52M | 26.83M | 39.58M | 10.15M |
| Short long term debt | 16.29M | 31.98M | 23.21M | 36.26M | 10.15M |
| Short long term debt total | 134.50M | 237.58M | 169.39M | 290.78M | 233.29M |
| Other stockholder equity | 1939.29M | 1464.29M | 1122.88M | 738.66M | 577.19M |
| Property plant equipment | 51.97M | 41.33M | 31.86M | 29.89M | 24.38M |
| Total current assets | 96.37M | 172.99M | 86.23M | 67.59M | 179.56M |
| Long term investments | 17.18M | 51.27M | 256.40M | 25.23M | 27.98M |
| Net tangible assets | -235.78M | -260.48M | 47.92M | -23.02M | 104.89M |
| Short term investments | 26.34M | 90.22M | 256.40M | - | 0.30M |
| Net receivables | 24.47M | 18.71M | 15.51M | 14.51M | 4.36M |
| Long term debt | 19.13M | 110.63M | 92.26M | 199.09M | 223.14M |
| Inventory | 9.98M | 8.11M | 1.83M | 3.36M | 2.90M |
| Accounts payable | 47.52M | 27.41M | 24.71M | 27.63M | 13.82M |
| Noncontrolling interest in consolidated entity | -3.06M | -0.62M | -24.42M | -45.83M | -1.97M |
| Accumulated other comprehensive income | 1.50M | 1.03M | 0.52M | -0.27M | 0.01M |
| Common stock total equity | 0.05M | 0.03M | 0.03M | 0.02M | 0.01M |
| Retained earnings total equity | -1959.45M | -1386.60M | -958.28M | -659.82M | -367.75M |
| Treasury stock | -49.46M | -49.46M | -49.46M | -49.46M | -49.46M |
| Non currrent assets other | -37.97M | -73.25M | -60.88M | -10.43M | 50.57M |
| Non current assets total | 376.47M | 521.83M | 449.59M | 490.04M | 444.52M |
| Capital lease obligations | 99.09M | 94.97M | 53.93M | 55.43M | - |
| Long term debt total | 19.13M | 110.63M | 92.26M | 199.09M | 223.14M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -28.52M | 124.77M | -39.92M | -38.17M | -21.20M |
| Change to liabilities | 16.41M | 16.76M | 0.08M | 19.96M | 15.46M |
| Total cashflows from investing activities | -28.52M | 79.85M | -39.92M | -38.17M | -21.20M |
| Net borrowings | -92.24M | -35.91M | -186.98M | 25.41M | 173.38M |
| Total cash from financing activities | 311.72M | 181.33M | 174.24M | 78.89M | 326.00M |
| Change to operating activities | - | 5.07M | 8.89M | 8.59M | 7.31M |
| Net income | -577.76M | -429.14M | -314.41M | -363.01M | -212.53M |
| Change in cash | -13.03M | -19.80M | -24.30M | -132.56M | 192.90M |
| Begin period cash flow | 36.66M | 56.46M | 80.77M | 213.33M | 20.43M |
| End period cash flow | 23.63M | 36.66M | 56.46M | 80.77M | 213.33M |
| Total cash from operating activities | -293.86M | -281.82M | -159.54M | -173.00M | -111.77M |
| Issuance of capital stock | 402.33M | 201.82M | 317.87M | 47.70M | 83.61M |
| Depreciation | 13.24M | 12.46M | 11.01M | 10.99M | 9.05M |
| Other cashflows from investing activities | -14.86M | 34.54M | -33.40M | -26.73M | -10.00M |
| Change to inventory | -9.51M | 8.62M | 10.20M | - | - |
| Change to account receivables | -5.68M | -2.96M | -1.05M | -10.62M | -1.62M |
| Sale purchase of stock | 403.53M | 217.25M | -55.00M | 56.55M | 61.35M |
| Other cashflows from financing activities | 97.69M | 65.16M | 116.94M | 34.26M | 288.12M |
| Change to netincome | 284.29M | 118.97M | 136.37M | 151.01M | 65.40M |
| Capital expenditures | 13.66M | 8.87M | 37.58M | 11.44M | 11.20M |
| Change receivables | -5.68M | -2.96M | -1.05M | -10.62M | -1.62M |
| Cash flows other operating | -14.85M | 11.29M | 8.47M | 18.68M | 11.92M |
| Cash and cash equivalents changes | -10.66M | -20.64M | -25.22M | -132.28M | 193.04M |
| Change in working capital | 69.55M | -2.79M | 3.80M | 7.25M | 6.00M |
| Stock based compensation | 74.85M | 90.19M | 31.42M | 12.65M | 6.21M |
| Other non cash items | 128.09M | 83.39M | 110.77M | 159.50M | 85.62M |
| Free cash flow | -307.51M | -290.69M | -197.12M | -184.44M | -122.96M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SRNE Sorrento Therape |
- -% |
0.00 | - | 1.18 | 0.00 | 4.01 | 2.06 | -0.25 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
4955 Directors Place, San Diego, CA, United States, 92121
858 203 4100
949
| Name | Title | Year Born |
|---|---|---|
| Dr. Henry H. Ji Ph.D. | Chairman, President & CEO | 1964 |
| Dr. Scott Schaus Ph.D. | Chief Technology Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.